Back to state act
Description
On 28 January 2021, the Norwegian Medicines Agency introduced an export notification on rivaroxaban; certain immunoglobulins (IOVIG 100MG/ML, 300 ml hgl; hizentra 200 mg/ml, 10x10 ml hgl; 200 mg/ml, 2...
Sign in to see full description
Intervention Details
Intervention Type
Export licensing requirement
MAST Chapter
P: Export-related measures (incl. subsidies)
Implementation date
28 Jan 2021
Revocation date
01 Jul 2023
Implementation level
National
Affected flow
Outward
Announced as temporary
Yes
Eligible firms
all
Affected Trading Partners
Table
Affected Sectors
Sign in to access 1 sectors
Affected Products
Sign in to access 7 products
Threads
See all
This intervention is not part of any Thread yet.